- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The company is currently challenging an Income Tax demand of INR 962.75 Crores arising from the non-deduction of TDS related to a substantial remittance of INR 3,045 Crores for the acquisition of intellectual property from GSK Group entities. Following the appeal process, the Assessing Officer has ordered the company to pay 20% of the total outstanding amount, which translates to INR 192.55 Crores. This payment was executed on 28th November 2024, attributed to funds received under an indemnification claim according to a Sale and Purchase Agreement. Notably, this remittance is not expected to impact the company's financials at this stage, but investors should monitor the resolution of the overall demand as it may evolve.